News | August 27, 2022
Aurobindo Pharma Foundation and Rotary Clubs donated 800 bicycles
The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive
The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive
99% of Pristyn Doctors are using EMR facility on its doctor app
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
~96% decline reported in Malaria cases in Madhya Pradesh, due to public-private-people partnership
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
New deal strengthens Congenica’s presence in India
AI-driven company anumana partnered with Novartis to drive the development of its electrocardiogram (ECG) AI algorithms to detect subclinical heart disease.
Subscribe To Our Newsletter & Stay Updated
